Abstract 367P
Background
Radiologically defined sarcopenia has been associated with adverse oncological outcomes, with CT imaging being an expedient tool for determining sarcopenia in cancer patients. The objective of this meta-analysis is to assess the association of sarcopenia defined on CT head and neck with survival in head and neck cancer patients.
Methods
Following a PROSPERO-registered protocol, three reviewers conducted a systematic review of the PubMed, Embase and Cochrane Library for observational studies that reported the presence of sarcopenia in association with mortality estimates. Two blinded reviewers extracted data and evaluated the quality of included studies using the Quality of Prognostic Studies tool and the Grading of Recommendations, Assessment, Development and Evaluations framework. A meta-analysis was conducted using maximally adjusted hazard ratios for mortality estimates and correlation coefficients. Heterogeneity was investigated using meta-regression and subgroup analyses.
Results
From 33 studies (9083 participants), sarcopenia was associated with poorer overall survival (HR, 2.09; 95% CI, 1.77 to 2.47; p = .01), disease-free survival (HR, 1.76; 95% CI, 1.38 to 2.24; p < .01) disease-specific survival (HR, 2.24; 95% CI, 1.82 to 3.67; p < .01), progression-free survival (HR, 2.24; 95% CI, 1.82 to 3.67; p < .01) and increased chemotherapy or radiotherapy toxicity (RR, 2.28; 95% CI, 1.31 to 3.95; p < .01). Overall survival was significantly poorer in studies with mean BMI <25 kg/m2 compared with studies with mean BMI ≥25 kg/m2. The observed association between sarcopenia and overall survival remained significant across different locations of cancer, treatment modality, tumor stages and geographical region, and did not differ between univariate and multivariate hazard ratios. Statistically significant correlations were observed between C3 and L3 cross-sectional area, skeletal muscle mass and skeletal muscle index.
Conclusions
Among patients with head and neck cancers, CT-defined sarcopenia was consistently associated with poorer survival and greater toxicity. Our findings are easily applicable in clinical practice, by measuring sarcopenia at the C3 vertebra on routine staging CT scans.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National University of Singapore.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract